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ABSTRACT 
Transdermal drug delivery is another system which provides controlled and continuous delivery of the drug through the skin into the systemic circulation. 
Topical application which involves drug transport to viable epidermal and/or dermal tissues of the skin for local therapeutic effect while a very major fraction 
of drug is transported into the systemic blood circulation. Transdermal route provides many advantages over conventional oral and invasive methods of drug 
delivery such as avoids first pass metabolism, improve patient compliance, maintance steady state plasma concentration. This article provides an overview of 
skin  permeation  pathways,  types  of  transdermal  drug  delivery  system,  methods  of  preparation  with  different  methods  of  evaluation,  and  the  recent 
advancement in transdermal drug delivery, which includes Transfersomes, Magnetophoresis, Controlled Heat Aided Drug Delivery System, Laser Radiation, 
Medicated Tattoos, Laser radiation. 
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INTRODUCTION 
Conventional  systems  of  medication  require  multi  dose 
therapy to deliver the right amount of medicine at the right 
target  site,  which  becomes  complicated  if  each medication 
were to be delivered in an optimal and preferred manner to 
the  individual  patient.  The  design  of  conventional  dosage 
form whether it is in tablet form or injection form or in a 
patch form, has to be delivered in an optimal manner, which 
becomes complicated
1-2. 
Optimum therapeutic outcomes required not only proper drug 
selection but also effective drug delivery. Innovations in drug 
delivery  system,  offer  substantial  clinical  advantages 
including  reduced  dosage  frequency;  improved  patient 
compliance & minimized fluctuation of the concentration and 
maintenance  of  drug  blood  level  within  desired  range  and 
reduced adverse effects. The creation of transdermal delivery 
system  has  been  one  of  the  most  important  of  these 
innovations
3. 
Controlled drug release can be achieved by transdermal drug 
delivery  system  (TDDS);  also  known  as  “Patches”,  are 
dosage forms designed to deliver a therapeutically effective 
amount of drug across a patient’s skin to systemic circulation 
at a predetermined rate over a prolonged period of time
4-5.
 
FDA approved the first transdermal patch products in 1981. 
These  delivery  systems  provided  the  controlled  systemic 
absorption  of  scopolamine  for  the  prevention  of  motion 
sickness  (Transderm-scop,  ALZA  corp.)  and nitroglycerine 
for the prevention of angina pectoris associated with coronary 
artery disease (Transderm-Nitro).Over the last two decades, 
more  than  35  transdermal  products  have  been  approved 
generating sales of $3.2 billion in 2002, which is predicted to 
rise to $4.5 billion in 2008.More recently, such dosage forms 
have been developed and/or modified in order to enhance the 
driving  force  of  drug  diffusion  (thermodynamic  activity) 
and/or  increase  the  use  of  penetration  enhancers  for 
transdermal  products  the  goal  of  dosage  design  is  to 
maximize  the  flux  through  the  skin  into  the  systemic 
circulation  and  simultaneously  minimize  the  retention  and 
metabolism of the drug in the skin
6-8. 
Advantages of transdermal drug delivery systems
9 
Delivery  via  the  transdermal route  is  an  interesting  option 
because  transdermal  route  is  convenient  and  safe.  The 
positive features of delivery drugs across the skin to achieve 
systemic effects are avoidance of first pass metabolism and 
gastro  intestinal  incompatibility,  predictable  and  extended 
duration  of  activity,  minimizing  undesirable  side  effects, 
provides utilization of drugs with short biological half lives 
and narrow therapeutic window, Greater patient compliance 
due to elimination of multiple dosing profile. 
Disadvantages of transdermal drug delivery systems
10 
Only  small  lipophilic  drugs  can  be  delivered  currently 
through  the  skin,  avoids  peak  and  trough  drug  levels  and 
longer  multiday  dosing  interval,  drug  molecule  must  be 
potent because patch size limits amount that can be delivered 
and also not suitable for high drug doses which will show 
skin irritation and hypersensitivity reactions. 
Since the human skin is a readily accessible surface for drug 
delivery. Skin of an average adult body covers a surface of 
approximately 2 m
2 and receives about one-third of the blood 
circulating  through  the  body.  Skin  contains  an  uppermost 
layer, epidermis which has morphologically distinct regions; 
basal layer, spiny layer, stratum granulosum and upper most 
stratum  corneum,  it  consists  of  dead  cells  embedded  in  a 
continuous  matrix  of  lipid  membranous  sheets.  These 
extracellular membranes are unique in their compositions and 
are composed of ceramides, cholesterol and free fatty acids. 
The human skin surface is known to contain, on an average, 
10-70 hair follicles and 200-250 sweat ducts on every square 
centimeters  of  the  skin area.  It  is  one  of  the  most  readily 
accessible  organs  of  the  human  body
11.Transdermal  drug 
delivery  the  delivery  of  drugs  across  the  skin  and  into 
systemic circulation is distinct from topical drug penetration, 
which  targets  local  areas.  Transdermal  drug  delivery  takes 
advantage of the relative accessibility of the skin
12. 
Pathway of Transdermal permeation
13-14 
Permeation can occur by diffusion via. 
 
a) The appendgeal route 
  Skin  appendages  provide  a  continuous  channel  directly 
across the stratum corneum barrier.  However, their influence 
on drug penetration is hindered by a number of factors. The 
surface area occupied by hair follicles and sweat ducts are 
small (typically 0.1% of skins surface area), thus limiting the 
area  available  for  direct  contact  of  the  applied  drug 
formulation. 
b) Transcellular route 
Drugs  entering  the  skin  via  the  transcellular  route  pass 
through  corneocytes  containing  highly  hydrate  keratin 
provide  an  aqueous  environment  for  which  hydrophilic Vandana Yadav et al: Transdermal Drug Delivery 
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drugs can pass. The diffusion pathway for a drug via the 
transcellular  route  requires  a  number  of  partitioning  and 
diffusion steps. 
c) Intercellular route 
 The intercellular pathway involves drug diffusing through 
the continuous lipid matrix. This route is a significant 
obstacle for two reasons.  
·  Recalling  the ‘bricks and  mortar’ model  of  the  stratum 
corneum,  the  interdigitating  nature  of  the  corneocytes 
yields  a  tortuous  pathway  for  intercellular  drug 
permeation, which is in contrast to the relatively direct 
path of the transcellular route.  
·  The  intercellular  domain  is  a  region  of  alternating 
structured  bilayers.  Consequently,  a  drug  must 
sequentially partition into, and diffuse through repeated 
aqueous  and  lipid  domains.    This  route  is  generally 
accepted as the most common path for small uncharged 
molecules penetrating the skin.   
Skin status or conditions for Drug permeation
15 
·  Hydration: Hydrated skin is more permeable than dry 
skin.                                         
·  Broken or irritated skin: Drugs can more easily bypass 
the stratum corneum, increases permeability. 
·  Temperature: Warmer skin is more permeable. 
·  Sunburn: Initially skin is less permeable; after peeling, it 
becomes more permeable. 
·  Eczema/ Psoriasis: Regions exhibit increased/decreased 
permeability. 
·  Skin peels: Removal of the stratum corneum increases 
permeability. 
Basic components of Transdermal Drug delivery system 
a) Drug 
For  successfully  developing  a  TDDS,  the  drug  has  to  be 
chosen with great care. Some of the desirable properties of a 
drug and factors to be considered for transdermal delivery are 
shown in Table 1 & 2
17. 
These  are  some  examples  of  drugs  which  are  suitable  for 
TDDS  like  Nicardipine  hydrochloride,  Captopril,  Atenolol, 
Metoprolol  tartrate,  Clonidine,  Indapamide,  Propranolol 
hydrochloride,  Carvedilol,  Verapamil  hydrochloride  and 
Nitrendipine  etc
16. 
b) Release liner 
During storage the patch is covered by a protective liner that 
is removed and discarded immediately before the application 
of the patch to skin. It is therefore regarded as a part of the 
primary packaging material rather than a part of dosage form 
for delivering the drug. Liner should be chemically inert and 
permeable  to  the  drug,  penetration  enhancer  and  water. 
Typically, release liner is composed  of a base layer which 
may  be non-occlusive (e.g. paper fabric) or occlusive (e.g. 
polyethylene, polyvinylchloride) and a release coating layer 
made up of silicon or Teflon
18-19. 
c) Polymer matrix / drug reservoir 
Polymers  are  the  backbone  of  a  TDDS,  which  control  the 
release of the drug from the device. Polymer matrix can be 
prepared  by  dispersion  of  drug  in  liquid  or  solid  state 
synthetic polymer base. Polymers used in TDDS should have 
both good stability as well as compatibility with the drug and 
other  components  of  the  system  and  they  should  provide 
effective release of a drug throughout the device with safe 
status
20. 
 
 
Various Techniques which are employed to modify the 
Polymer properties and thus Drug Release Rates
21-22  
Techniques of matrix  
·  Cross linked polymers: The higher the degree of cross 
linking, the denser the polymer and slower the diffusion 
of drug molecules through the matrix.  
·  Polymer blends: Polymers have been blended on varying 
ratios  to  combine  the  advantages  of  the  individual 
polymers.Advantages  of  polymer  blends  include  easy 
fabrication of devices, manipulation of drug loading and 
other  devices  properties  such  as  hydration,  degradation 
rate and mechanical strength.  
·  Plasticizers:Plasticizers have been known to reduce the 
stiffness of the polymer backbone, thereby increasing the 
diffusion  characteristics  of  the  drug.  Commonly  used 
plasticizers  are  polyethylene  glycol,  propylene  glycol, 
glycerol, dibutyl phthalate.  
The polymers used for TDDS can be classified as in Table 
3
23. 
·  The  polymers  like  polyethylene  glycol
24,  Eudragit
25, 
ethylcellulose, polyvinylpyrrolidone
26 and hydroxypropyl 
methylcellulose
27 are used as matrix type TDDS.              
·   The polymers like EVA
28, silicon rubber and 
polyurethane
29 are used as rate controlling TDDS. 
d) Permeation enhancers 
One long-standing approach for improving transdermal drug 
delivery by using penetration enhancers (also called sorption 
promoters  or  accelerants)  which  penetrate  into  skin    to 
increase permeability of stratum corneum by interacting with 
structural  components  of  stratum  corneum  i.e.  proteins  or 
lipids to attain higher therapeutic levels of the drug
30. They 
alter the protein and lipid packaging of stratum corneum, thus 
chemically  modifying  the  barrier  functions  leading  to 
increased permeability
31. 
Some of the more desirable properties for penetration 
enhancers acting within skin have been 
Given as
32 
·  They should be non-toxic, non-irritating and non 
allergenic. 
·  They  would  ideally  work  rapidly;  the  activity  and 
duration  of  effect  should  be  both        predictable  and 
reproducible. 
·  They should have no pharmacological activity within the 
body, i.e. should not bind to receptor sites. 
·  The penetration enhancers should work unidirectionally. 
·  When removed  from the skin, barrier properties should 
return both rapidly and fully. 
·  The  penetration  enhancers  should  be  appropriate  for 
formulation into diverse topical preparations, thus should 
be compatible with both excipients and drugs. 
Some  example  are  Dimethyl 
sulfoxide(DMSO),Glycol(Propylene  glycol),  2-Pyrrolidone, 
Isopropyl  myristate,  Laurocapram  (Azone),  Sodium  lauryl 
sulfate,  Sorbitan  monolaurate,  Pluronic,  Cardamom  oil, 
Caraway oil, Lemon oil, Menthol, dlimonene, Linoleic acid
33. 
e) Pressure sensitive adhesives 
An approach to explain the adhesive properties of pressure 
sensitive adhesives (PSAs) is based on the belief that the PSA 
will  adhere  to  a  skin,  because  of  inter  atomic  and 
intermolecular  attractive  forces  established at the  interface, 
provided that intimate contact is achieved
34-35.To obtain this 
degree of contact, the material must be able to deform under 
slight pressure, giving rise to the term ‘‘pressure sensitive.’’ Vandana Yadav et al: Transdermal Drug Delivery 
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Adhesion involves a liquid-like flow resulting in wetting of 
the skin surface upon the application of pressure, and when 
pressure is removed, the adhesive sets in that state. PSA/skin 
bond  can  be  built  by  stronger  interactions  (e.g.  hydrogen 
bonding), which will depend on skin characteristics and other 
parameters. The PSA should be compatible with the drug and 
excipients  since  their  presence  can  modify  the  mechanical 
characteristics of the PSA and the drug delivery rate
36.PSAs 
used in commercially available Transdermal systems include 
polyacrylate, polyisobutylene, and polysiloxane
37. 
f) Backing laminate 
Backing  materials  must  be  flexible  while  possessing  good 
tensile strength. Commonly used materials are polyolefin’s, 
polyesters, and elastomers in clear, pigmented, or metalized 
form. Elastomeric materials such as low-density polyethylene 
conform more readily to skin movement and provide better 
adhesion than less compliant materials such as polyester. In 
systems containing drug within a liquid or gel, the backing 
material must be heat-sealable to allow fluid-tight packaging 
of the drug reservoir using a process known as form-fill-seal. 
The  most  comfortable  backing  exhibits  lowest  modulus  or 
high flexibility, good oxygen transmission and high moisture 
vapour transmission rate
38-39. 
Examples  of  some  backing  materials  are  vinyl,  polyester 
films,  Polyester-polypropylene  films,  Polypropylene  resin, 
Polyethylene  resin,  Polyurethylene,  Co  Tran  9722  film, 
Ethylene-vinyl acetate, Aluminized plastic laminate. 
 g) Other excipients 
Various  solvents  such  as  chloroform,  methanol,  acetone, 
isopropanol and dichloromethane are     used to prepare drug 
reservoir
40.  In  addition  plasticizers  such  as  dibutylpthalate, 
triethylcitrate, polyethylene glycol and propylene glycol are 
added to provide plasticity to the Transdermal patch
40-41. 
TYPES  OF  TRANSDERMAL  DRUG  DELIVERY 
SYSTEM
42-43 
I) Reservoir systems 
In this system, the drug reservoir is embedded between an 
impervious backing layer and a rate controlling membrane. 
The  drug  releases  only  through  the  rate-controlling 
membrane, which can be microporous or nonporous. In the 
drug reservoir compartment, the drug can be in the form of a 
solution, suspension, or gel or dispersed in a solid polymer 
matrix. On the outer surface of the polymeric membrane a 
thin  layer  of  drug-compatible,  hypoallergenic  adhesive 
polymer can be applied. 
II) Matrix systems 
a)  Drug-in-adhesive system 
The drug reservoir is formed by dispersing the drug in an 
adhesive polymer and then spreading the medicated polymer 
adhesive by solvent casting or by melting the adhesive (in the 
case of hot-melt adhesives) onto an impervious backing layer. 
On  top  of  the  reservoir,  layers  of  unmedicated  adhesive 
polymer are applied. 
b)   Matrix-dispersion system 
The  drug  is  dispersed  homogeneously  in  a  hydrophilic  or 
lipophilic polymer matrix. This drug containing polymer disk 
then is fixed onto an occlusive base plate in a compartment 
fabricated from a drug-impermeable backing layer. Instead of 
applying the adhesive on the face of the drug reservoir, it is 
spread along the circumference to form a strip of adhesive 
rim. 
III) Microreservoir systems 
This drug delivery system is a combination of reservoir and 
matrix-dispersion systems. The drug reservoir is formed by 
first  suspending the  drug  in  an  aqueous  solution  of  water-
soluble  polymer  and  then  dispersing  the  solution 
homogeneously in a lipophilic polymer to form thousands of 
unleachable,  microscopic  spheres  of  drug  reservoirs.  The 
thermodynamically unstable dispersion is stabilized quickly 
by  immediately  cross-linking  the  polymer  in  situ  by  using 
cross-linking agents. 
VARIOUS METHODS OF PREPARATION OF TDDS  
a) Circular teflon mould method  
Solutions containing polymers in various ratios are used in an 
organic solvent. Calculated amount of drug is dissolved in 
half  the  quantity  of  same  organic  solvent.  Enhancers  in 
different concentrations are dissolved in the other half of the 
organic  solvent  and  then  added.  Di-N-butyl  phthalate  is 
added as a plasticizer into drug polymer solution stirred for 
12 hrs.  The moulds are to be placed on a leveled surface and 
covered with inverted funnel to control solvent vaporization 
in a laminar flow hood model with an air speed of 0.5 m/s. 
The  solvent  is  allowed  to  evaporate  for  24  hrs.  The  dried 
films are to be stored for another 24 hrs at 25±0.5 °C in a 
desiccators  containing  silica  gel  before  evaluation  to 
eliminate aging effects. The type films are to be evaluated 
within one week of their preparation
44.  
b) Mercury substrate method
 
In this method drug is dissolved in polymer solution along 
with plasticizer. The above solution is to be stirred for 10- 15 
minutes to produce a homogenous dispersion and poured in 
to a leveled mercury surface, covered with inverted funnel to 
control solvent evaporation
45.  
c) By using “EVAC membranes” method  
In order to prepare the target transdermal therapeutic system, 
1% carbopol reservoir gel, polyethelene (PE), ethylene vinyl 
acetate copolymer (EVAC) membranes can be used as rate 
control  membranes.  If  the  drug  is  not  soluble  in  water, 
propylene glycol is used for the preparation of gel. Drug is 
dissolved in propylene glycol; carbopol resin will be added to 
the above solution and neutralized by using 5% w/w sodium 
hydroxide  solution. The  drug  (in  gel  form) is  placed  on  a 
sheet  of  backing  layer  covering  the  specified  area.  A  rate 
controlling  membrane  will  be  placed  over  the  gel  and  the 
edges will be sealed by heat to obtain a leak proof device
46. 
d) Aluminium backed adhesive film method 
Transdermal  drug  delivery  system  may  produce  unstable 
matrices  if  the  loading  dose  is  greater  than  10  mg. 
Aluminium backed adhesive film method is a suitable. The 
drug is dissolved in chloroform and adhesive material will be 
added  to  the  drug  solution  and  dissolved.  A  custammade 
aluminium former is lined with aluminium foil and the ends 
blanked off with tightly fitting cork blocks
47.  
e) Preparation of TDDS by using Proliposomes
 
The proliposomes are prepared by carrier method using film 
deposition  technique.  The  proliposomes  are  prepared  by 
taking 5mg of mannitol powder in a 100 ml round bottom 
flask which is kept at 60-70 °C temperature and the flask is 
rotated at 80-90 rpm and dried the mannitol at vacuum for 30 
minutes. After drying, the temperature of the water bath is 
adjusted to 20-30 °C. Drug and lecithin are dissolved in a 
suitable  organic  solvent  mixture,  a  0.5  mL  aliquot  of  the 
organic solution is introduced into the round bottomed flask 
at 37 °C, after complete drying second aliquots (0.5 mL) of 
the solution is to be added. After the last loading, the flask 
containing proliposomes are connected in a lyophilizer and 
subsequently drug loaded mannitol powders (proliposomes) 
are placed in a desiccator over night and then sieved through Vandana Yadav et al: Transdermal Drug Delivery 
JPSI 1 (1), JAN – FEB 2012, 5-12 
100 mesh. The collected powder is transferred into a glass 
bottle  and  stored  at  the  freeze  temperature  until 
characterization
48-49.  
f) By using free film method
 
Free  film  of  cellulose  acetate  is  prepared  by  casting  on 
mercury  surface.  A  polymer  solution  2%  w/w  is  to  be 
prepared  by  using  chloroform.  Plasticizers  are  to  be 
incorporated  at  a  concentration  of  40%  w/w  of  polymer 
weight.5 mL of polymer solution was poured in a glass ring 
which is placed over the mercury surface in a glass petridish. 
The rate of evaporation of the solvent is controlled by placing 
an inverted funnel over the petridish. The film formation is 
noted  by  observing  the  mercury  surface  after  complete 
evaporation of the solvent. The dry film will be separated out 
and stored between the sheets of wax paper in a desiccator 
until use. Free films of different thickness can be prepared by 
changing the volume of the polymer solution
50.  
EVALUATION OF TDDS 
1. Physicochemical Evaluation 
A) Interaction studies 
The  drug  and the  excipients must  be  compatible  with  one 
another  to  produce  a  product  that  is  stable,  thus  it  is 
mandatory  to  detect  any  possible  physical  or  chemical 
interaction as it can affect the bioavailability and stability of 
the  drug.  Interaction  studies  are  commonly  carried  out  in 
Thermal  analysis,  FT-IR,  UV  and  chromatographic 
techniques  by  comparing  their  physicochemical  characters 
such  as  assay,  melting  endotherms,  characteristic  wave 
numbers, and absorption maxima
51. 
B) Thickness of the patch 
The thickness of the drug loaded patch is measured by using 
a  digital  micrometer  at  different  point  of  patch  and 
determines  the  average  thickness  and  also  the  standard 
deviation for the same to ensure the thickness of the prepared 
patch
52. 
C) Weight uniformity  
The prepared patches are to be dried at 60 °C for 4hrs before 
testing. A specified area of patch is to be cut in different parts 
of the patch and weigh in digital balance. The average weight 
and standard deviation values are to be calculated from the 
individual weights
52.  
D) Folding endurance  
A  strip  of  specific  are  is  to  be  cut  evenly  and  repeatedly 
folded at the same place till it broke. The number of times the 
film could be folded at the same place without breaking gives 
the value of the folding endurance
52.  
E) Percentage Moisture content  
The prepared films are to be weighed individually and to be 
kept  in  a  desiccator  containing  fused  calcium  chloride  at 
room temperature for 24 hrs. After 24 hrs the films are to be 
reweighed  and  determine  the  percentage  moisture  content 
from the below mentioned formula
52.  
Percentage moisture Content = [Initial weight- Final weight/ 
Final weight] ×100  
F) Percentage Moisture uptake  
The  weighed  films  are  kept  in  a  desiccator  at  room 
temperature  for  24  hrs  containing  saturated  solution  of 
potassium chloride in order to maintain 84% RH. After 24 
hrs  the  films  are  to  be  reweighed  and  determine  the 
percentage  moisture  uptake  from  the  below  mentioned 
formula
52.  
Percentage Moisture Uptake = [Final weight- Initial weight/ 
initial weight] ×100  
 
G) Water vapour permeability (WVP) evaluation  
Water  vapour  permeability  can  be  determined  with  foam 
dressing method the air forced oven is replaced by a natural 
air  circulation  oven.  The  WVP  can  be  determined  by  the 
following formula
35 
WVP=W/A  
Where, WVP is expressed in gm/m
2 per 24hrs,  
W is the amount of vapour permeated through the patch 
expressed in gm/24hrs and  
A is the surface area of the exposure samples expressed in 
m
2.  
H) Drug content   
A  specified  area  of  patch  is  to  be  dissolved  in  a  suitable 
solvent in specific volume. Then the solution is to be filtered 
through a filter medium and analyze the drug contain with the 
suitable method (UV or HPLC technique). Then the average 
of three different samples is taken
53.  
I) Uniformity of dosage unit test  
An accurately weighed portion of the patch is to be cut into 
small pieces and transferred to a specific volume volumetric 
flask,  dissolved  in  a  suitable  solvent  and  sonicate  for 
complete extraction of drug from the patch and made up to 
the mark with same. The resulting solution was allowed to 
settle  for  about  an  hour,  and  the  supernatant  was  suitably 
diluted  to  give  the  desired  concentration  with  suitable 
solvent. Suitable analytical technique (UV or HPLC) and the 
drug content for each piece are to be calculated
54. 
J) Polariscope examination  
This test is to be performed to examine the drug crystals from 
patch by polariscope. A specific surface area of the piece is to 
be kept on the object slide and observe for the drugs crystals 
to distinguish whether the drug is present as crystalline form 
or in amorphous form in the patch
54. 
K) Shear Adhesion test  
Shear adhesion strength is determined by measuring the time 
taken to pull the adhesion coated tape off a stainless steel 
plate. The  longer the  time take  for removal, greater is  the 
shear strength
54.  
L) Peel Adhesion test  
In this test, a single tape is applied to a stainless steel plate or 
a backing membrane of choice and then tape is pulled from 
the substrate at a 180º angle, and the force required for tape 
removed is measured
54. 
M) Thumb tack test  
It is a qualitative test applied for tack property determination 
of adhesive. The thumb is simply pressed on the adhesive and 
the relative tack property is detected
54.  
N) Flatness test 
  
Three  longitudinal  strips  are  to  be  cut  from  each  film  at 
different portion like one from the center, other one from the 
left side, and another one from the right side. The length of 
each strip was measured and the variation in length because 
of non-uniformity in flatness was measured by determining 
percent constriction, with 0% constriction equivalent to 100% 
flatness
55.  
O) Percentage elongation break test
 
The percentage elongation break is to be determined by 
noting the length just before the break point, the percentage 
elongation can be determined from the below mentioned 
formula
56.  
Elongation percentage = L1-L2 ×100  
  L2  
Where, L1is the final length of each strip and  
L2 is the initial length of each strip.  Vandana Yadav et al: Transdermal Drug Delivery 
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P) Rolling ball tack test 
 
This test measures the softness of a polymer that relates to 
talk. In this test, stainless steel ball of 7/16 inches in diameter 
is  released  on  an  inclined  track  so  that  it  rolls  down  and 
comes into contact with horizontal, upward facing adhesive. 
The distance the ball travels along the adhesive provides the 
measurement of tack, which is expressed in inch
57.  
Q) Quick Stick (peel-tack) test   
 In this test, the tape is pulled away from the substrate at 90ºC 
at a speed of 12 inches/min. The peel force required breaking 
the  bond  between  adhesive  and  substrate  is  measured  and 
recorded as tack value, which is expressed in ounces or grams 
per inch width
58.  
R) Probe Tack test
 
 In this test, the tip of a clean probe with a defined surface 
roughness is brought into contact with adhesive, and when a 
bond is formed between probe and adhesive. The subsequent 
removal  of  the  probe  mechanically  breaks  it.  The  force 
required to pull the probe away from the adhesive at fixed 
rate is recorded as tack and it is expressed in grams
58. 
2. In vitro Evaluation of TDDS 
a. In vitro drug release studies 
It is one chambered (vertical) type cell. Most widely used for 
in-vitro  testing  of  TDDS.  Many  modifications  have  been 
made  in  the  Franz  diffusion  cell  design  according  to  the 
requirement. Here skin is mounted on the plate above O ring. 
20-70 ml phosphate buffer of pH 7.4 (physiological pH) is 
filled in reservoir compartment. Transdermal patch is applied 
on  upper  layer  of  skin.  Diffusion  medium  in  reservoir  is 
stirred  at  particular  rpm.  Sampling  is  done  at  particular 
interval from reservoir compartment i.e. specified volume of 
fluid is withdrawn and is replaced by equivalent amount of 
the same fluid
59. 
b. In vitro skin permeation studies
 
An  in  vitro  permeation  study  can  be  carried  out  by  using 
diffusion cell. Full thickness abdominal skin of male Wistar 
rats weighing 200 to 250g. The temperature of the cell was 
maintained at 32 ± 0.5 °C using a thermostatically controlled 
heater. The isolated rat skin piece is to be mounted between 
the  compartments  of  the  diffusion  cell,  with  the  epidermis 
facing upward into the donor compartment. Sample volume 
of  definite  volume  is  to  be  removed  from  the  receptor 
compartment  at  regular  intervals,  and  an  equal  volume  of 
fresh medium is to be replaced. Samples are to be  filtered 
through  filtering  medium  and  can  be  analyzed 
spectrophotometrically  or  H  LC
51.  Flux  can  be  determined 
directly  as  the  slope  of  the  curve  between  the  steady-state 
values of the amount of drug permeated mg cm
2 vs time in 
hours and permeability coefficients were deduced by dividing 
the flux by the initial drug load mg cm
2. 
3 In vivo Evaluation
 
 A)  In  vivo  evaluations  are  the  true  depiction  of  the  drug 
performance.  The  variables  which  cannot  be  taken  into 
account during in vitro studies can be fully explored during in 
vivo studies. In vivo evaluation of TDDS can be carried out 
using
33: 
· Animal  models:  The most  common  animal  species  used 
for evaluating transdermal drug delivery system are mouse, 
hairless  rat, hairless  dog,  hairless  rhesus  monkey,  rabbit, 
guinea pig etc. Various experiments conducted lead us to a 
conclusion  that  hairless  animals  are  preferred  over  hairy 
animals in both in vitro and in vivo experiments, Rhesus 
monkey  is  one  of  the  most  reliable  models  for  in  vivo 
evaluation of transdermal drug delivery in man. 
·  Human models: The final stage of the development of a 
transdermal device involves collection of pharmacokinetic 
and  pharmacodynamic  data  following  application  of  the 
patch  to  human  volunteers.  Clinical  trials  have  been 
conducted to assess the efficacy, risk involved, side effects, 
patient compliance etc. Phase I clinical trials are conducted 
to  determine  mainly  safety  in  volunteers  and  phase  II 
clinical  trials  determine  short  term  safety  and  mainly 
effectiveness in patients. Phase III trials indicate the safety 
and effectiveness in large number of patient population and 
phase IV trials at post marketing surveillance are done for 
marketed patches to detect adverse drug reactions. 
·  Skin Irritation study  
Skin irritation and sensitization testing can be performed on 
healthy rabbits and gunia pigs  (average weight 1.2 to 1.5 
kg).  The  dorsal  surface  (50cm2)  of  the  rabbit  is  to  be 
cleaned and remove the hair from the clean dorsal surface 
by shaving and clean the surface by using rectified spirit 
and the representative formulations can be applied over the 
skin. The patch is to be removed after 24 hr and the skin is 
to be observed and classified into 5 grades on the basis of 
the severity of skin injury
54.  
·   Stability studies
 
Stability studies are to be conducted according to the ICH 
guidelines by storing the TDDS samples at 40±0.5°c and 
75±5% RH for 6 months. The samples were withdrawn at 
0, 30, 60, 90 and 180 days and analyze suitably for the drug 
content
51.  
RECENT ADVANCEMENT IN TDDS 
The way of releasing a medicament effectively has taken up a 
great advancement based on the oversaturation of an adhesive 
polymer with medication, thus propel the drug from reservoir 
by a partial crystallization of the drug. The presence of both 
molecular  solute  and  solid  crystal  Transdermal  drug 
absorption markedly alters drug kinetics. The toxic effect of 
the  drug  and  problem  in  limiting  drug  uptake  are  major 
considerable  potential  for  transdermal  delivery  systems, 
especially in children because skin thickness and blood flow 
in the skin usually vary with age. The increased blood supply 
in the skin along with thinner skin has significant effects on 
the pharmacokinetics of transdermal delivery for children. In 
some situations this may be an advantageous, while in others 
systemic toxicity may occur. This was observed after using 
scopolamine patches that are used to prevent motion sickness, 
a eutectic mixture of local anesthetics (EMLA) cream used to 
minimize the pain, corticosteroid cream applied for its local 
effect on skin maladies. Episodes of systemic toxic effects, 
including some fatalities in children, have been documented 
with each of these, often secondary to accidental absorption 
through mucous membranes
60.              
Pharmaceutical  companies  are  now  developing  new 
adhesives, substances that enhance molecular absorption as 
well as penetration that will ultimately affect skin permeation 
and greatly increase the list of drugs which can be delivered 
transdermally.  Well  known  technologies  that  are 
iontophoresis  and  phonophoresis  (sonophoresis)  considered 
to  acheive  significant  plasma  concentration  levels  via  skin 
membrane. A microoneedle technology is more promising for 
drug  administered  via  skin.  These  systems  use  an 
arrangement of small needle-like structures to open pores in 
the stratum cornea and facilitate drug transport without any 
sensation of pain because these are not reachable to nerve 
endings. These systems are reported to greatly enhance the 
permeability of macromolecules across skin.  Vandana Yadav et al: Transdermal Drug Delivery 
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FUTURE CHALLENGES 
The statical data showed a market of $ 12.7 billion in the year 
2005 which is assumed to increase by $ 21.5 billion in the 
year 2010 and $ 31.5 billion in the year 2015. Almost all the 
pharmaceutical  companies  are  developing  TDDS
61. 
Extending the patent term of older drugs by formulating them 
in new  dosage  forms has generated  enthusiasm  among  the 
pharmaceutical  scientists  to  develop  new  dosage  forms.  In 
addition, new dosage forms are essential for other drugs in 
order to enhance their performance by reducing their dose, 
increasing absorption, delivering to the target site etc. The 
patented innovations in transdermal drug delivery arena aim 
at these goals. However, the ultimate test that an innovative 
technique should pass relates to its successful performance in 
vivo.  Hence,  the  formulator  faces  a  challenging  task  of 
translating  the  patented  claims  to  actual  practice.  It  is 
important to note that none of the generic fentanyl patches 
awaiting approval by US FDA could be launched in 2005. 
Similarly, the Evra patch landed into trouble as women using 
it were found to be at greater risk of blood clots. The article 
by  Batheja  and  Michniak  (2006)  gives  an  analysis  of  US 
patents  on  transdermals  filed  in  2005  and  shall  aid  the 
formulator  in  his  quest  for  making  percutaneous  drug 
delivery  more  effective  and  patient  compliant
62. 
Commercially  available  Transdermal  Products  which  are 
given in Table 4
62. 
CONCLUSION 
Successful  transdermal  drug  application  requires  the 
desirable physicochemical properties for penetration through 
stratum corneum. Bearing in mind that the basic functions of 
the  skin  are  protection  and  containment,  it  would  seem 
exceptionally  difficult  to  target  the  skin  for  drug  delivery. 
However, with our greater understanding of the structure and 
function of the skin, and how to alter these properties, more 
and  more  new  drug  products  are  being  developed  for 
transdermal  delivery.  The  properties  of  the  drug,  the 
characteristics of the transdermal device, selection of in-vivo 
model and the status of patient’s skin are all important for 
safe and effective drug delivery. 
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Table 1: Ideal properties of drug for TDDS 
Parameters 
 
Properties 
Dose  Should be low (less than 20 mg/day) 
Half-life  10/less (hrs) 
 
Molecular weight  < 400 Da 
 
Partition co-efficient  Log P (octanol-water) 
between 1.0-4.0 
Skin permeability coefficient 
 
> 0.5×10-3 cm/h 
 
Skin reaction  Non irritating and no sensitizing 
 
Oral bioavailability  Low 
 
Therapeutic index  Low 
 
Melting Point  < 2000F 
 
pH  Between 5.0-9.0 
 
 
Table 2: Factors to be considered for transdermal dose calculation 
Physicochemical  Pharmacokinetic  Biological 
 
Solubility  Half-life 
 
Skin toxicity 
Crystallinity  Volume of distribution 
 
Site of application 
Molecular 
weight 
Total body clearance  Allergic reaction 
Polarity  Therapeutic plasma concentration  Skin metabolism 
 
Melting point  Bioavailable factor 
 
 
 
Table 3: Polymers used in transdermal devices 
Natural Polymers 
 
Synthetic Elastomer  Synthetic Polymers 
 
 
Cellulose derivatives, Zein, 
Gelatin, Shellac, Waxes, 
Proteins, Gums and their 
derivatives, Natural rubber, 
Starch, etc. 
 
 
 
Polybutadiene, Hydrin rubber, 
Polysiloxane, Silicone rubber, 
Nitrile, Acrylonitrile, Butyl 
Rubber, Styrene-butadiene rubber, Neoprene, 
etc. 
 
Polyvinyl alcohol, Polyvinyl chloride, 
Polyethylene, Polypropylene, 
Polyacrylate, 
Polyamide, Polyurea, Polyvinyl 
pyrrolidone, 
Polymethyl methacrylate, Epoxy, Ethyl 
cellulose, etc. 
 Vandana Yadav et al: Transdermal Drug Delivery 
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Table 4: List of Transdermal Products 
Product name(active drug)  Matrix or 
Membrane Patch 
Duration of 
Application 
Indication 
Alora(Estradiol)  Matrix  3 to 4 days  Post Menstrual Syndrome 
Androderm(Testosterone)  Membrane  24 hours  Hypogonadism(males) 
 
CatapresTTS(Clonidine)  Membrane  7 days  Hypertension 
 
Climara(Estadiol)  Matrix  7 days  Post Menstrual Syndrome 
Combipach(Estradiol/Norethindrone acetate)  Matrix  3 to 4 days  Hormone Replacement Therapy 
Duragesic(Fentaryl)  Membrane  72 hours  Moderate/Severe Pain 
 
Estradem(Estradiol)  Membrane  3 to 4 days  Post Menstrual Syndrome 
Minitran(Nitroglycerin)  Matrix  12 to 16 hours  Angina Pectoris 
Nicoderm(Nicotine)  Membrane  24 hours  Smoking Cessation 
 
Nicotrol(Nicotine)  Matrix  16 hours  Smoking Cessation 
 
Nitradisc(Nitroglycerin)  Matrix  24 hours  Angina Pectoris 
 
Nitrodur(Nitroglycerin)  Matrix  12 to16 hours  Angina Pectoris 
Ortho-Evra(Norelgestromin/estradiol)  Matrix  7 days  Birth Control 
 
 